ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
Launched by ONWARD MEDICAL, INC. · Jul 4, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment called ARC-IM Therapy, which aims to help people with spinal cord injuries manage their blood pressure and improve their ability to control their trunk movements. The therapy involves implanting a device that sends gentle electrical signals to the spinal cord, helping to restore the body's natural control over blood pressure, especially for those experiencing orthostatic hypotension (a drop in blood pressure when standing up). This study is currently recruiting participants who are 18 years or older with a traumatic spinal cord injury at specific levels of the spine and who have had their injury for at least one month.
To be eligible, participants must be able to understand and communicate in Dutch or English and should not have certain health conditions that would complicate the surgery or the study. Those who join the trial can expect to have the device implanted, and they will be closely monitored for safety and effectiveness. It’s important for participants to regularly attend appointments and, if needed, bring a caregiver to help with transportation and support. Overall, this trial is an important step towards improving the quality of life for individuals with spinal cord injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age or older
- • Must provide and sign the Informed Consent prior to any study-related procedures
- • Traumatic Spinal Cord Injury
- • Spinal cord injury lesion level between C3 and T6 (inclusive)
- • AIS- A, B, C or D
- • SCI ≥ 1month
- • Confirmed orthostatic hypotension
- • Stable medical, physical and psychological condition as considered by the investigators
- • Able to understand and interact with the study team in Dutch or English
- • Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments
- • In case participants need continuous support from a personal caregiver in daily life, then the presence of their caregiver during the visits to the study site is needed, including independent transport (not dependent on a cab)
- Exclusion Criteria:
- • Diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery
- • Diseases and conditions that would require regular MRI
- • The inability to perform an MRI due to metal, magnetic or electrical device in the body (e.g. oral implant with magnet, mtal splinter, neurostimulator, artificial heart valve, clips, stents...) as assessed by the MRI form of Sint Maartenskliniek
- • The inability to withhold antiplatelet/anticoagulation agents perioperatively
- • History of myocardial infarction or cerebrovascular event within the past 6 months
- • Other conditions that would make the subject unable to participate in testing in the judgement of the investigators
- • Clinically significant mental illness in the judgement of the investigators
- • Botulinum toxin non-vesical and vesical injections in the previous 3 months before the enrolment
- • Presence of significant pressure ulcers
- • Recurrent urinary tract infection refractory to antibiotics
- • Presence of indwelling baclofen (e.g. intrathecal baclofen pump) or insulin pump
- • Women who are pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding
- • Lack of safe contraception for women of childbearing capacity
- • Intention to become pregnant during the course of the study,
- • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
- • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, or dementia of the participant
- • Participation in another study with investigational drug within the 30 days preceding and during the present study
- • Enrolment of the investigator, his/her family members, employees, and other dependent persons
About Onward Medical, Inc.
Onward Medical, Inc. is a pioneering biotechnology company dedicated to advancing innovative therapies for individuals with neurological disorders. With a focus on developing cutting-edge treatments that enhance the quality of life for patients with spinal cord injuries and other debilitating conditions, Onward Medical leverages state-of-the-art technology and rigorous clinical research methodologies. The company's commitment to scientific excellence and patient-centric solutions positions it at the forefront of neuromodulation and rehabilitation, aiming to restore mobility and independence for those affected by severe neurological challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ubbergen, , Netherlands
Patients applied
Trial Officials
Ilse Van Nes, MD, PhD
Principal Investigator
Sint Maartenskliniek, department of rehabilitation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported